Timur Dogan
Chief Tech/Sci/R&D Officer at CARDIO DIAGNOSTICS HOLDINGS, INC.
Net worth: 88 943 $ as of 2024-05-30
Timur Dogan active positions
| Companies | Position | Start | End |
|---|---|---|---|
| CARDIO DIAGNOSTICS HOLDINGS, INC. | Chief Tech/Sci/R&D Officer | 2022-10-24 | - |
Career history of Timur Dogan
Former positions of Timur Dogan
| Companies | Position | Start | End |
|---|---|---|---|
Cardio Diagnostics, Inc.
 Cardio Diagnostics, Inc. Medical/Nursing ServicesHealth Services Part of Cardio Diagnostics Holdings, Inc., Cardio Diagnostics, Inc. is a biotechnology company based in Chicago, IL. The company is focused on making cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company's flagship solution, the Cardio Diagnostics Epi+Gen CHD™ test, helps clinicians better assess each patient's unique risk profile for disease. The company's vision is to transform medical care for cardiovascular disease from reactive to proactive. Cardio Diagnostics was founded in 2017 by Meeshanthini Dogan and Robert Philibert, with Meeshanthini Dogan serving as CEO since then. Cardio Diagnostics was acquired by Mana Capital Acquisition Corp. on October 25, 2022 for $61.51 million. | Chief Tech/Sci/R&D Officer | 2022-04-30 | - |
Training of Timur Dogan
| University of Iowa | Doctorate Degree |
Statistics
International
| United States | 4 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 1 |
| Graduate Degree | 1 |
Sectoral
| Health Technology | 2 |
| Health Services | 2 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| CARDIO DIAGNOSTICS HOLDINGS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Cardio Diagnostics, Inc.
Cardio Diagnostics, Inc. Medical/Nursing ServicesHealth Services Part of Cardio Diagnostics Holdings, Inc., Cardio Diagnostics, Inc. is a biotechnology company based in Chicago, IL. The company is focused on making cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company's flagship solution, the Cardio Diagnostics Epi+Gen CHD™ test, helps clinicians better assess each patient's unique risk profile for disease. The company's vision is to transform medical care for cardiovascular disease from reactive to proactive. Cardio Diagnostics was founded in 2017 by Meeshanthini Dogan and Robert Philibert, with Meeshanthini Dogan serving as CEO since then. Cardio Diagnostics was acquired by Mana Capital Acquisition Corp. on October 25, 2022 for $61.51 million. | Health Services |
- Stock Market
- Insiders
- Timur Dogan
- Experience
